NACDS continues to urge the vital need for reforms at the federal level that will prevent “pharmaceutical benefit manipulation” across all markets – Medicare, Medicaid and commercial.
Report: “The Committee’s findings indicate that the present role of PBMs in prescription drug markets is failing and requires change”
NACDS urges “tenacity” by House Oversight and Accountability Committee in its hearing and investigation.
A coalition of organizations representing pharmacies and pharmacists across all practice settings released a statement today ahead of a Tuesday, July 23 U.S. House Committee on Oversight and Accountability hearing on PBM middlemen tactics.
HB 1993 includes important PBM reforms and protections for Pennsylvania families’ access to pharmacies for important services.
NACDS: “The Congress and states need no further validation for their bipartisan work to immediately confront pharmaceutical benefit manipulation that is devastating Americans, communities, and pharmacies of all sizes”
NACDS: “These harms are experienced brutally by pharmacies of diverse sizes and formats, including independents and chains, that do not receive preferential treatment from their vertically integrated plans and PBMs”
“Now is the time for Massachusetts to stop pharmaceutical benefit manipulation from inflating Bay Staters’ prescription drug prices and from jeopardizing access to trusted pharmacies and needed medications”
“Confronting the PBMs’ self-enriching tactics requires state and federal legislators and policymakers to do their part”
“Confronting the PBMs’ self-enriching tactics requires state and federal legislators and policymakers to do their part.”
PBMs represent a “staggering national problem.”
Urges Congress: no further delays in enacting bipartisan reforms to reduce Americans’ drug costs and to protect access to pharmacies and prescribed medications.
